Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pyxis Oncology (PYXS) Gross Margin (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Gross Margin for 2 consecutive years, with 100.0% as the latest value for Q2 2025.

  • On a quarterly basis, Gross Margin changed N/A to 100.0% in Q2 2025 year-over-year; TTM through Sep 2025 was 100.0%, a N/A change, with the full-year FY2024 number at 97.06%, changed N/A from a year prior.
  • Gross Margin was 100.0% for Q2 2025 at Pyxis Oncology, up from 97.06% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 100.0% in Q2 2025 to a low of 97.06% in Q1 2024.